Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Obesity Week 2022More Weight Loss With Surgery Than New Obesity Meds: Meta-AnalysisWeight loss was lower with a GLP-1 agonist than with bariatric surgery, in a small review article and meta-analysis, but researchers have yet to directly compare surgery with new dual or triple agonists.
Medscape Medical News, November 17, 2022
Obesity Week 2022Tirzepatide Lowers Weight Across All Groups With Obesity The anti-obesity medication semaglutide (Wegovy) 'took things up one big notch, and now tirzepatide [which is still awaiting approval for weight loss] is up a little notch above that,' one expert commented.
Medscape Medical News, November 7, 2022
Obesity Week 2022New Dual Agonist Weight Loss Injection Impressive, But Early Days The 'bottom line' is that this potential new anti-obesity/diabetes drug is 'very promising, but [it is] still a little early to say where it ultimately will go,' says one obesity expert.
Strong Support for Laws Against Weight Discrimination, BullyingThere was nearly unanimous support for policies protecting youth against weight-related bullying and strong support for laws
against such discrimination in the workplace, in a six-country survey.
Medscape Medical News, Nov 08, 2021
'If Obesity Were Diabetes or Cancer, How Would You Approach It?'There's so much misinformation about obesity, says an expert. 'People think it's a lack of willpower, and even patients blame
themselves for not being able to lose weight and keep it off. It's not their fault! It's biology.
Medscape Medical News, Nov 04, 2021
More STEP Data: Semaglutide Cuts Weight, Cravings, Beats LiraglutideIn STEP 5, weight loss with semaglutide was sustained at 2 years and the drug cut cravings in a subgroup; in STEP 8, semaglutide
beat liraglutide for weight loss at 68 weeks. There were no new safety signals.
